An­oth­er biotech scoops up as­set from Chi­na-based Keymed and nabs $180M

Two biotechs emerged on Fri­day with as­sets from Keymed Bio­sciences, ex­tend­ing a pro­lif­er­at­ing trend of West­ern in­vestors prop­ping up new com­pa­nies to fur­ther de­vel­op as­sets …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER